Li-Fraumeni Syndrome Clinical Trial
Official title:
Evaluate Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling Based on LFSPRO-ShinyApp Data
This study evaluates patients willingness to participate in a trial comparing standard genetic counseling versus personalized genetic counseling. Collecting information from patients may help researchers learn why patients may or may not take part in the future study that compares standard genetic counseling to personalized genetic counseling.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | October 2, 2027 |
Est. primary completion date | February 2, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Individuals age 15 or older OR parent/guardian of a patient younger than 15 years (if age 15-17, the patient will provide assent and parent/guardian will provide consent) - English fluency - Receive genetic counseling specifically for TP53 genetic testing and who consent to undergo TP53 genetic testing OR individuals whose genetic testing indicates a TP53 germline mutation Exclusion Criteria: - Individuals who are non-English speaking - Individuals having low suspicion for a TP53 germline mutation during pretest counseling and test negative for a TP53 mutation |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient willingness to participate in a future randomized trial comparing standard genetic counseling versus personalized genetic counseling based on LFSPRO ShinyApp data | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04367246 -
Li-Fraumeni Syndrome/TP53 Biobank
|
||
Recruiting |
NCT04541654 -
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
|
||
Completed |
NCT01737255 -
Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome
|
||
Active, not recruiting |
NCT02950987 -
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes
|
N/A | |
Enrolling by invitation |
NCT03176836 -
Li-Fraumeni Syndrome Imaging Study
|
N/A | |
Recruiting |
NCT01143454 -
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
|
||
Completed |
NCT02289326 -
Biomarker Monitoring in TP53 Mutation Carriers
|
||
Recruiting |
NCT04982744 -
Registry of Li Fraumeni and Li Fraumeni Like Syndromes
|
||
Completed |
NCT01981525 -
A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome
|
Phase 1 | |
Completed |
NCT00406445 -
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
|
||
Recruiting |
NCT01443468 -
Clinical and Genetic Studies of Li-Fraumeni Syndrome
|
||
Completed |
NCT04966923 -
Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53
|
||
Recruiting |
NCT06088030 -
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
|
Phase 2 | |
Recruiting |
NCT03050268 -
Familial Investigations of Childhood Cancer Predisposition
|